U.S. Venture Partners XII L.P. 13D and 13G filings for ARS Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-01-27 3:05 pm Sale | 2021-12-13 | 13D | ARS Pharmaceuticals, Inc. SPRY | U.S. Venture Partners XII L.P. | 110,120 0.300% | -2,160,360 (-95.15%) | Filing |
| 2020-12-14 06:05 am Purchase | 2020-12-04 | 13D | ARS Pharmaceuticals, Inc. SPRY | U.S. Venture Partners XII L.P. | 2,270,480 6.500% | 2,270,480 (New Position) | Filing |